{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:16:55Z","timestamp":1774585015253,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jpeds.2018.08.065","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T09:26:27Z","timestamp":1539249987000},"page":"162-171.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses"],"prefix":"10.1016","volume":"204","author":[{"given":"Florence A.","family":"Aeschlimann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ling","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-1070","authenticated-orcid":false,"given":"Todd W.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate C.","family":"Beinvogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina Maria","family":"G\u00f3ez-Mogoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Laxer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2018.08.065_bib0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","article-title":"Systemic-onset juvenile idiopathic arthritis","volume":"15","author":"Cimaz","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0020","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1002\/art.30569","article-title":"Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis","volume":"63","author":"Morbach","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0025","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/annrheumdis-2014-206424","article-title":"Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis","volume":"74","author":"van den Broek","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0040","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0045","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2013-204641","article-title":"Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register","volume":"74","author":"Otten","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0055","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0060","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0075","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0080","series-title":"Cochrane handbook for systematic reviews of interventions versions 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0090","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0100","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2016","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0110","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0120","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0125","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0130","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","article-title":"A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study","volume":"15","author":"Hissink Muller","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0140","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0145","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0150","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0155","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0165","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0170","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0175","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0190","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0195","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0200","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0205","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0220","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0225","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0230","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0235","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0240","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","article-title":"The safety profile of biologic therapies for juvenile idiopathic arthritis","volume":"6","author":"Hashkes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0245","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-associated infections in pediatric rheumatology","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the german biologics in pediatric rheumatology registry","volume":"69","author":"Becker","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0255","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the british society for paediatric and adolescent rheumatology etanercept cohort study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0260","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/rheumatology\/kex049","article-title":"Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis","volume":"57","author":"Lee","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0265","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0270","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0280","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jpeds.2018.08.065_bib0285","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1209","article-title":"Infectious complications with the use of biologic response modifiers in infants and children","volume":"138","author":"Davies","year":"2016","journal-title":"Pediatrics"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618312393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618312393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T04:52:46Z","timestamp":1545195166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347618312393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":56,"alternative-id":["S0022347618312393"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.08.065","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.08.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}